Loading…
Entrada Therapeutics, Inc. is projected to rise to $7.43 by 2027, a +12% move from its current price of $6.63. TRDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.36 | $6.63 | $6.91 | +0.03% |
| May 30 | $6.26 | $6.63 | $7.04 | +0.07% |
| May 31 | $6.18 | $6.64 | $7.13 | +0.10% |
| Jun 1 | $6.11 | $6.64 | $7.22 | +0.14% |
| Jun 2 | $6.05 | $6.64 | $7.29 | +0.17% |
| Jun 3 | $6.00 | $6.64 | $7.36 | +0.20% |
| Jun 4 | $5.95 | $6.65 | $7.42 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.95 | $6.65 | $7.42 | +0.24% |
| Week 2 | $5.70 | $6.66 | $7.78 | +0.48% |
| Week 3 | $5.52 | $6.68 | $8.08 | +0.72% |
| Week 4 | $5.37 | $6.69 | $8.34 | +0.96% |
| Week 5 | $5.24 | $6.71 | $8.58 | +1.20% |
| Week 6 | $5.13 | $6.73 | $8.81 | +1.44% |
| Week 7 | $5.04 | $6.74 | $9.02 | +1.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Its Endosomal Escape Vehicle and therapeutic candidates are based on a novel therapeutic approach, with a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Its preclinical products include ENTR-601-44, ENTR-601-45, and VX-670.
The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Entrada Therapeutics, Inc. trades under the symbol TRDA and is currently priced at $6.56. It has a market capitalization of $254.66M and is ranked 3654 by market capitalization/size metrics.
The current price sits within a broader forecast that envisions upside over time, with the average price rising through the late decade and into the 2040s and 2050s. Notable points include a 2026 avg of $6.56, a 2029 avg of $10.84, a 2030 avg of $13.19, and a 2050 avg of $75.18, with a max forecast of $170.84 in 2050 and a long-run bullish tilt according to the series of yearly projections.
A major floor 14.8% below — a decisive break under it would weaken the trend.
The nearest floor, 14.8% below — buyers have tended to step in here.
The nearest ceiling, 141.8% above — a clean break opens room to run.
A major ceiling 198.9% above — clearing it would confirm fresh momentum.
Key TRDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.45 | Buy | $6.54 | Buy |
| MA 10 | $6.43 | Buy | $6.96 | Sell |
| MA 20 | $9.02 | Sell | $8.34 | Sell |
| MA 50 | $11.37 | Sell | $10.27 | Sell |
| MA 100 | $11.36 | Sell | $10.63 | Sell |
| MA 200 | $9.35 | Sell | $10.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.05 | Neutral |
| Stoch RSI (14) | 96.38 | Sell |
| CCI (20) | -46.64 | Neutral |
| Williams %R (14) | -41.32 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -3.07 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 58.68 | Neutral |
| TRIX (15) | -2.10 | Sell |
| Awesome (5,34) | -4.39 | Sell |
| Ultimate (7,14,28) | 40.37 | Neutral |
| Momentum (10) | -0.49 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 6.69 | Sell |
| ADX (14) | 33.49 | Sell |
| ATR (14) | 0.55 | Info |
The 30-day technical picture shows sentiment as NEUTRAL, with RSI14 at 30. The stock trades around key averages, with SMA50 at $11.61 and SMA200 at $9.34, signaling a price format below both moving averages.
Support is identified at $5.65 and resistance at $16.03. The 30-day price range runs from $4.91 to $8.77, illustrating a near-term trading band. Annualized volatility is high at 80%, underscoring substantial near-term price movement potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.65 | $6.63 | $9.86 | 0% | Neutral | |
| $5.59 | $7.43 | $10.61 | +12% | Neutral | |
| $5.56 | $7.72 | $11.59 | +16% | Neutral | |
| $7.34 | $10.58 | $16.53 | +60% | Bullish | |
| $8.72 | $13.00 | $21.00 | +96% | Bullish | |
| $9.42 | $14.49 | $24.08 | +119% | Bullish | |
| $10.07 | $15.95 | $27.20 | +141% | Bullish | |
| $9.85 | $16.03 | $27.98 | +142% | Bullish | |
| $9.84 | $16.46 | $29.33 | +148% | Bullish | |
| $10.53 | $18.08 | $32.85 | +173% | Bullish | |
| $14.12 | $27.40 | $53.99 | +313% | Bullish | |
| $32.09 | $71.32 | $157.77 | +976% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.65 | $6.63 | $7.89 | +0.00% |
| June 2026 | $5.81 | $6.90 | $8.45 | +4.09% |
| July 2026 | $5.68 | $6.84 | $8.54 | -0.91% |
| August 2026 | $5.84 | $7.10 | $9.01 | +3.89% |
| September 2026 | $6.16 | $7.55 | $9.70 | +6.33% |
| October 2026 | $6.09 | $7.52 | $9.77 | -0.42% |
| November 2026 | $5.87 | $7.30 | $9.58 | -2.93% |
| December 2026 | $5.95 | $7.45 | $9.86 | +2.01% |
Click any year to see its month-by-month TRDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Entrada Therapeutics, Inc.'s 2026 outlook centres on $6.63, within a $5.65 to $9.86 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TRDA could reach as high as $10.61, with a base case around $7.43 and support toward $5.59 — roughly +12% from $6.63. A consolidation phase looks the most probable path here.
Expect TRDA to range from $5.56 to $11.59 through 2028. The $7.72 average target implies a +16% move from current prices. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
The TRDA price prediction for 2029 points to an average of $10.58 (low $7.34, high $16.53) — a potential gain of +60% on today's $6.63. Buyers look set to stay in control over this stretch.
In 2030, TRDA is projected to trade between $8.72 and $21.00, averaging $13.00 — a potential gain of +96% from today's $6.63. That is up +23% on the projected 2029 average. Momentum favours further upside here.
Entrada Therapeutics, Inc.'s 2031 outlook centres on $14.49, within a $9.42 to $24.08 range. That is up +11% on the projected 2030 average. That marks a +119% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TRDA could reach as high as $27.20, with a base case around $15.95 and support toward $10.07 — roughly +141% from $6.63. Momentum favours further upside here.
Expect TRDA to range from $9.85 to $27.98 through 2033. The $16.03 average target implies a +142% move from current prices. That is up +1% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TRDA price prediction for 2034 points to an average of $16.46 (low $9.84, high $29.33) — a potential gain of +148% on today's $6.63. Momentum favours further upside here.
In 2035, TRDA is projected to trade between $10.53 and $32.85, averaging $18.08 — a potential gain of +173% from today's $6.63. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Entrada Therapeutics, Inc.'s 2040 outlook centres on $27.40, within a $14.12 to $53.99 range. That is up +52% on the projected 2035 average. That marks a +313% change versus current levels. Momentum favours further upside here.
By 2050, TRDA could reach as high as $157.77, with a base case around $71.32 and support toward $32.09 — roughly +976% from $6.63. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRDA today (≈ 150.829563 TRDA) could be worth
$10,756.58
+$9,756.58 (+976%) by 2050 · US Dollar
Based on the average projected TRDA price of $71.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRDAwould be worth at today's price.
$1,000 invested in TRDA on May 27, 2025 (≈ 129.870133 TRDA) would be worth
$861.04
-$138.96 (-13.9%) today · 0.86× · US Dollar
Based on a TRDA entry price of $7.7 vs. today's $6.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.04 | $1,097.68 | +9.8% |
| 1 month ago | $12.96 | $511.57 | -48.8% |
| 3 months ago | $12.79 | $518.37 | -48.2% |
| 6 months ago | $10.27 | $645.57 | -35.4% |
| 1 year ago | $7.7 | $861.04 | -13.9% |
| All time (4.6y) ago | $23.95 | $276.83 | -72.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRDA forecast.
Our base-case forecast reaches $13.00 around 2030.
Implied market cap at $13.00: $504.67M
The year-by-year forecast implies meaningful long-horizon upside. For 2026, the min is $5.65, the avg is $6.56, the max is $9.94, with a current-coded neutral stance.
In 2027, the min is $5.47, the avg is $7.34, the max is $10.60, with a forecast ROI of 11.8 and a neutral sentiment.
The 2028 forecast shows a min of $5.45, an avg of $7.66, and a max of $11.66, with a 16.7 ROI and neutral sentiment; 2029 carries a min of $7.41, an avg of $10.84, and a max of $17.19, with a 65.2 ROI and a bullish sentiment. By 2030, the min rises to $8.70, the avg to $13.19, and the max to $21.65, with a 101 ROI and bullish sentiment.
Further years show continuing bullish momentum: 2031 min $9.40, avg $14.74, max $24.92, ROI 124.6; 2032 min $10.19, avg $16.49, max $28.63, ROI 151.4; 2033 min $9.71, avg $16.20, max $28.82, ROI 147; 2034 min $9.71, avg $16.68, max $30.32, ROI 154.3; 2035 min $10.63, avg $18.79, max $34.86, ROI 186.5, all with bullish sentiment.
The forecast continues with a strong uplift into the 2040s and 2050s: 2040 min $14.03, avg $28.34, max $57.18, ROI 332.1, bullish; and 2050 min $33.83, avg $75.18, max $170.84, ROI 1046, bullish. These projections illustrate substantial long-term upside with a bullish tilt while recognizing that these are estimates, not guarantees.
Tap a question to reveal the answer.
The 2030 forecast lists a min of $8.70, an avg of $13.19, and a max of $21.65, with a predicted ROI of 101 and a bullish sentiment.
The long-term forecast points to upside, with an average price reaching $75.18 by 2050 and an ROI of 1046, while earlier years show more modest gains (e.g., 2029 avg $10.84, ROI 65.2). These are estimates and not guarantees.
Yes, the 2050 forecast shows a max of $170.84, which exceeds $100, indicating a potential path above $100 according to the projections.
The 2026 forecast lists a min of $5.65, an avg of $6.56, and a max of $9.94.
The 2029 forecast shows a min of $7.41, an avg of $10.84, and a max of $17.19, with a ROI of 65.2 and a bullish sentiment.
Entrada Therapeutics, Inc. Community Discussion
0Share your Entrada Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.